Category: Advances in Drug Development
Chronic Myelogenous Leukemia Therapy Beyond Imatinib
Chronic Myelogenous Leukemia Therapy Beyond Imatinib Michael Deininger, MD, PhD, Section Head, Center for Hematologic Malignancies, Non-Transplant, Associate Professor, Oregon Health & Science University, Portland, Oregon H&O What are the […]
Controversies in the Design of Phase II Clinical Trials
Controversies in the Design of Phase II Clinical Trials Lesley Seymour, MD, PhD, Co-Director of the Investigational New Drug Program Director of the Audit and Monitoring Group of […]
BRAF Validation in Melanoma
BRAF Validation in Melanoma Keith Flaherty, MD, Director, Developmental Therapeutics Massachusetts General Hospital Boston, Massachusetts H&O What is BRAF and what role does it play in melanoma? KF V-raf murine […]
Targeting the Anti-apoptotic Signaling Pathway
Targeting the Anti-apoptotic Signaling Pathway Craig Thompson, MD, Scientific Director of the Abramson Institute, Chair of the Department of Cancer Biology, Professor of Medicine, Abramson Family Cancer Research Institute, Philadelphia, PA […]
B-RAF Validation in Melanoma
Neal Rosen, MD, PhD Professor of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York H&O What is B-RAF and what role does it play in melanoma? […]
ALK Inhibitors in Lung Cancer
Elisabeth Heath, MD Associate Professor of Medicine and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan H&O What is the background on the anaplastic lymphoma kinase (ALK) fusion […]